Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024; 404: 1321–32—The appendix for this Article has been updated as of Oct 31, 2024.

中文翻译：

---

 错误部门


Lorusso D， Xiang Y， Hasegawa K， et al. 帕博利珠单抗或安慰剂联合放化疗，然后帕博利珠单抗或安慰剂治疗新诊断的高危局部晚期宫颈癌 （ENGOT-cx11/GOG-3047/KEYNOTE-A18）：一项随机、双盲、安慰剂对照的 3 期试验的总生存期结果。柳叶刀 2024;404： 1321–32—本文附录已于 2024 年 10 月 31 日更新。